share_log

Transcode Therapeutics | DEF 14A: Definitive information statements

Transcode Therapeutics | DEF 14A: Definitive information statements

Transcode Therapeutics | DEF 14A：股東委託書決議
美股sec公告 ·  04/29 16:09
Moomoo AI 已提取核心訊息
Transcode Therapeutics, Inc. has announced the scheduling of its 2024 Annual Meeting of Stockholders to be held on June 13, 2024. The meeting will take place at the offices of Goodwin Procter LLP in Boston, MA. The company has outlined several key agenda items for the meeting, including the election of four directors, the approval of an amendment to increase the number of shares available under the company's 2021 Stock Option and Incentive Plan by 3,000,000 shares, and the ratification of WithumSmith+Brown, PC as the company's independent registered public accounting firm for the fiscal year ending December 31, 2024. The proxy statement and enclosed proxy card are being mailed to stockholders on or about May 3, 2024. Stockholders of record as of April 22, 2024, are entitled to vote at the meeting. The company encourages stockholders to vote their shares by proxy prior to the Annual Meeting.
Transcode Therapeutics, Inc. has announced the scheduling of its 2024 Annual Meeting of Stockholders to be held on June 13, 2024. The meeting will take place at the offices of Goodwin Procter LLP in Boston, MA. The company has outlined several key agenda items for the meeting, including the election of four directors, the approval of an amendment to increase the number of shares available under the company's 2021 Stock Option and Incentive Plan by 3,000,000 shares, and the ratification of WithumSmith+Brown, PC as the company's independent registered public accounting firm for the fiscal year ending December 31, 2024. The proxy statement and enclosed proxy card are being mailed to stockholders on or about May 3, 2024. Stockholders of record as of April 22, 2024, are entitled to vote at the meeting. The company encourages stockholders to vote their shares by proxy prior to the Annual Meeting.
Transcode Therapeutics, Inc.已宣佈其2024年年度股東大會的時間表定於2024年6月13日舉行。會議將在馬薩諸塞州波士頓的古德溫·寶潔律師事務所辦公室舉行。該公司概述了會議的幾個關鍵議程項目，包括選舉四名董事，批准一項修正案，將公司2021年股票期權和激勵計劃下的可用股票數量增加300萬股，以及批准WithumSmith+Brown, PC 作爲截至2024年12月31日的財年公司的獨立註冊會計師事務所。委託書和隨附的代理卡將於2024年5月3日左右郵寄給股東。截至2024年4月22日的登記股東有權在會議上投票。該公司鼓勵股東在年會之前通過代理人對股票進行投票。
Transcode Therapeutics, Inc.已宣佈其2024年年度股東大會的時間表定於2024年6月13日舉行。會議將在馬薩諸塞州波士頓的古德溫·寶潔律師事務所辦公室舉行。該公司概述了會議的幾個關鍵議程項目，包括選舉四名董事，批准一項修正案，將公司2021年股票期權和激勵計劃下的可用股票數量增加300萬股，以及批准WithumSmith+Brown, PC 作爲截至2024年12月31日的財年公司的獨立註冊會計師事務所。委託書和隨附的代理卡將於2024年5月3日左右郵寄給股東。截至2024年4月22日的登記股東有權在會議上投票。該公司鼓勵股東在年會之前通過代理人對股票進行投票。
有用
沒用

該公告為獨立文件：

獨立文件1  查看翻譯

声明：本內容僅用作提供資訊及教育之目的，不構成對任何特定投資或投資策略的推薦或認可。 更多信息